Inositol (in-o-sĭ-tol)


Essential for the growth of tissues, inositol is found in nine different forms (isomers), including myo-, d-chiro-, scyllo-, muco-, epi-, neo-, allo-, l-chiro-, and the synthetic cis-inositol (89). Myo-inositol (MI) and D-chiro-inositol (DCI) are the two main forms in our bodies (6) and most commonly used as supplements (87). Previously considered an essential B vitamin (vitamin B8), it is now known that the human body can synthesize four grams of inositol per day, whereas approximately one gram per day can be obtained from the diet (24). For this reason, inositol is now mainly referred to as an essential pseudovitamin (47). Inositol is a constituent of phospholipids in cellular membranes, a precursor of secondary messengers in metabolic pathways, and a component of reproductive fluids (62). It may play an important role in conditions related to insulin resistance, such as polycystic ovarian syndrome, metabolic syndrome, gestational diabetes, and other diabetic complications (20). Additionally, since MI can cross the blood-brain barrier, it may be beneficial in treating symptoms of affective disorders (67). Dietary sources of inositol are primarily found in fruits, beans, grains, and nuts (16).

Main Medical Uses

Polycystic ovarian syndrome (PCOS) may be treated with supplements containing inositol (3, 78), including MI (15, 19, 25, 28, 30, 33, 34, 35, 36, 50, 52, 72, 76, 79, 88, 90, 91, 94, 95, 98), DCI (30, 49, 69, 75), or their combination (4, 17, 51). Supplementation with MI is effective in reducing gonadotropin doses and the length of ovarian hyperstimulation in women with PCOS undergoing in vitro fertilization (55). It can similarly reduce gonadotropin doses in non-PCOS women (10) leading to a trend of increased implantation frequency (57). MI may lower birth weight (97) and reduce the risk of gestational diabetes (18, 21, 40, 61, 92, 96, 97). It may also reduce the risk of preterm delivery (40, 92, 96) and neonatal/infant death, retinopathy, and hemorrhage in respiratory distress syndrome (42, 43, 45). MI can also improve outcomes related to male fertility (9, 39). Inositol may be effective in treating panic disorder (5, 71). Metabolic syndrome can also be treated with inositol (63) or MI (37, 59, 83). There is some evidence to suggest that inositol supplementation may be effective in OCD (31), though it may not provide further benefits beyond those of serotonin reuptake inhibitors (32).

Dosing and Administration

For an explanation of the classes of evidence, please see the Rating Scales for Evidence-Based Decision Support.

Adverse Effects

At doses greater than 12g per day, gastrointestinal effects, such as nausea, flatulence, and diarrhea, may occur. However, the incidence of these events are considered mild and do not increase in severity as the dose increases (11). The use of MI in treating PCOS is associated with fewer adverse effects than metformin (28). Intravenous administration up to 80mg/kg/day of MI in infants did not increase the incidence of adverse events compared with placebo (74). Increasing doses (300-2400mg) of DCI has been shown to negatively impact oocyte quality in patients with PCOS (48).


Initially, the name “inositol” was given to the most abundant isomer found naturally. However, to distinguish it from the other eight forms, it was re-labelled as “myo-inositol”. The term “inositol” now encompasses all nine isomers, but MI remains the form that is often assumed when referring to inositol (29).

Isoforms of inositol take on differential physiological roles. Both MI and DCI are involved in insulin signaling; DCI is more involved in glycogenesis, while MI decreases intestinal absorption of glucose (14) and increases glucose uptake through glucose transporter activation and utilization (27). Each isomer has differences in tissue distribution and treatments combining MI and DCI have been based on an observed plasma ratio of 40:1 (26).

Associated Interactions and Depletions



Softgel capsules of MI (0.6g) are equally as bioavailable as powdered MI (2g) in healthy subjects (12). Intestinal transportation of MI across the apical membrane is accomplished by the sodium/inositol symporter 2 (SMIT2) (2). SMIT1/SMIT2 and the H+ myo-inositol transporter are responsible for inositol uptake throughout the body and brain (24). MI can pass the blood-brain barrier (85, 86).


MI oxygenase metabolizes MI to D-glucuronic acid in the renal cortical tubules. D-glucuronic acid is then converted by aldehyde reductase to L-gluconate. Metabolism of L-gluconate results in xylulose and ribulose, which both can be degraded through glycolysis (24).


If not reabsorbed by the SMT2 transporters on the apical membrane of the proximal convoluted tubules (56), both MI and DCI inositol are excreted in the urine (24).

Download the reference sheet
  1. Allan, S.J., Kavanagh, G.M., Herd, R.M., & Savin, J.A. (2004). The effect of inositol supplements on the psoriasis of patients taking lithium: a randomized, placebo-controlled trial. British Journal of Dermatology, 150(5), 966-9.
  2. Aouameur, R., Cal, S. D., Bissonnette, P., Coady, M. J., & Lapointe, J. (2007). SMIT2 mediates all myo-inositol uptake in apical membranes of rat small intestine. American Journal of Physiology-Gastrointestinal and Liver Physiology, 293(6).
  3. Arentz, S., Smith, C. A., Abbott, J., & Bensoussan, A. (2017). Nutritional supplements and herbal medicines for women with polycystic ovary syndrome; a systematic review and meta-analysis. BMC Complementary and Alternative Medicine,17(1).
  4. Benelli, E., Ghianda, S. D., Cosmo, C. D., & Tonacchera, M. (2016). A combined therapy with myo-inositol and d-chiro-inositol improves endocrine parameters and insulin resistance in PCOS young overweight women. International Journal of Endocrinology, 2016, 1-5.
  5. Benjamin, J., Levine, J., Fux, M., Aviv, A., Levy, D., & Belmaker, R. H. (1995). Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder. The American Journal of Psychiatry, 152(7), 1084-1086.
  6. Bizzarri, M., & Carlomagno, G. (2014). Inositol: History of an effective therapy for polycystic ovary syndrome. European Review for Medical and Pharmacological Sciences, 18(13), 1896-1903.
  7. Brink, C. B., Viljoen, S. L., Kock, S. E., Stein, D. J., & Harvey, B. H. (2004). Effects of myo-inositol versus fluoxetine and imipramine pretreatments on serotonin 5HT2A and muscarinic acetylcholine receptors in human neuroblastoma cells. Metabolic Brain Disease, 19(1/2), 51-70.
  8. Caldirola, D., & Perna, G. (2015). Is there a role for pharmacogenetics in the treatment of panic disorder? Pharmacogenomics, 16(8), 771-774.
  9. Calogero, A. E., Gullo, G., Vignera, S. L., Condorelli, R. A., & Vaiarelli, A. (2015). Myoinositol improves sperm parameters and serum reproductive hormones in patients with idiopathic infertility: A prospective double-blind randomized placebo-controlled study. Andrology, 3(3), 491-495.
  10. Caprio, F., D’Eufemia, M. D., Trotta, C., Campitiello, M. R., Ianniello, R., Mele, D., & Colacurci, N. (2015). Myo-inositol therapy for poor-responders during IVF: A prospective controlled observational trial. Journal of Ovarian Research, 8(1), 37.
  11. Carlomagno, G., & Unfer, V. (2011). Inositol safety: Clinical evidences. European Journal of Medical and Pharmacological Science, 15(8), 931-936.
  12. Carlomagno, G., Grazia, S. D., Unfer, V., & Manna, F. (2012). Myo-inositol in a new pharmaceutical form: A step forward to a broader clinical use. Expert Opinion on Drug Delivery, 9(3), 267-271.
  13. Carr, M. C. (2003). The emergence of the metabolic syndrome with menopause. The Journal of Clinical Endocrinology & Metabolism, 88(6), 2404-2411.
  14. Chukwuma, C. I., Ibrahim, M. A., & Islam, M. S. (2016). Myo-inositol inhibits intestinal glucose absorption and promotes muscle glucose uptake: A dual approach study. Journal of Physiology and Biochemistry, 72(4), 791-801.
  15. Ciotta, L., Stracquadanio, M., Pagano, I., Carbonaro, A., Palumbo, M., & Gulino, F. (2011). Effects of myo-inositol supplementation on oocyte’s quality in PCOS patients: A double blind trial. European Review for Medical and Pharmacological Sciences, 15, 509-514.
  16. Clements, R. S., & Darnell, B. (1980). Myo-inositol content of common foods: Development of a high-myo-inositol diet. The American Journal of Clinical Nutrition, 33(9), 1954-1967.
  17. Colazingari, S., Treglia, M., Najjar, R., & Bevilacqua, A. (2013). The combined therapy myo-inositol plus d-chiro-inositol, rather than d-chiro-inositol, is able to improve IVF outcomes: Results from a randomized controlled trial. Archives of Gynecology and Obstetrics, 288(6), 1405-1411.
  18. Corrado, F., D’Anna, R., Vieste, G. D., Giordano, D., Pintaudi, B., Santamaria, A., & Benedetto, A. D. (2011). The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes. Diabetic Medicine, 28(8), 972-975.
  19. Costantino, D., Minozzi, G., Minozzi, F., & Guaraldi, C. (2009). Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: A double-blind trial. European Review for Medical and Pharmacological Sciences, 13, 105-110.
  20. Croze, M. L., & Soulage, C. O. (2013). Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie, 95(10), 1811-1827.
  21. D’Anna, R., Di Benedetto, A., Scilipoti, A., Santamaria, A., Interdonato, M. L., Petrella, E., & Facchinetti, F. (2015). Myo-inositol supplementation for prevention of gestational diabetes in obese pregnant women: A randomized controlled trial. Obstetrics and Gynecology, 126(2), 310-315.
  22. Davanzo, P., Thomas. M.A., Yue, K., Oshiro, T., Belin, T., Strober, M., & McCracken, J. (2001). Decreased anterior cingulate myo-inositol/creatine spectroscopy resonance with lithium treatment in children with bipolar disorder. Neuropsychopharmacology, 24(4), 359-69.
  23. De Leo, V, Tosti, C., Cappelli, V., Morgante, G., & Cianci, E.A. (2014). Combination inositol and glucomannan in PCOS patients. Minerva Ginecologica, 66(6), 527-33.
  24. Dinicola, S., Minini, M., Unfer, V., Verna, R., Cucina, A., & Bizzarri, M. (2017). Nutritional and acquired deficiencies in inositol bioavailability: Correlations with metabolic disorders. International Journal of Molecular Sciences, 18(10), 2187.
  25. Donà, G., Sabbadin, C., Fiore, C., Bragadin, M., Giorgino, F. L., Ragazzi, E., . . . Armanini, D. (2012). Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome. European Journal of Endocrinology, 166(4), 703-710.
  26. Facchinetti, F., Bizzarri, M., Benvenga, S., D’Anna, R., Lanzone, A., Soulage, C., . . . Devroey, P. (2015). Results from the International Consensus Conference on Myo-inositol and d-chiro-inositol in Obstetrics and Gynecology: The link between metabolic syndrome and PCOS. European Journal of Obstetrics & Gynecology and Reproductive Biology, 195, 72-76.
  27. Facchinetti, F., Dante, G., & Neri, I. (2015). The ratio of MI to DCI and its impact in the treatment of polycystic ovary syndrome: Experimental and literature evidences. ISGE Series Frontiers in Gynecological Endocrinology,103-109.
  28. Facchinetti, F., Orrù, B., Grandi, G., & Unfer, V. (2019). Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): A meta-analysis of randomized clinical trials. Gynecological Endocrinology, 35(3), 198-206.
  29. Fisher, S. K., Novak, J. E., & Agranoff, B. W. (2002). Inositol and higher inositol phosphates in neural tissues: Homeostasis, metabolism and functional significance. Journal of Neurochemistry, 82(4), 736-754.
  30. Formuso, C., Stracquadanio, M., & Ciotta, L. (2015). Myo-inositol vs d-chiro inositol in PCOS treatment. Minerva Ginecologica, 67(4), 321-325.
  31. Fux, M., Levine, J., Aviv, A., & Belmaker, R. H. (1996). Inositol treatment of obsessive-compulsive disorder. The American Journal of Psychiatry, 153(9), 1219-1221.
  32. Fux, M., Benjamin, J., & Belmaker, R. H. (1999). Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive–compulsive disorder: A double-blind cross-over study. The International Journal of Neuropsychopharmacology,2(3), 193-195.
  33. Genazzani, A. D., Lanzoni, C., Ricchieri, F., & Jasonni, V. M. (2008). Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecological Endocrinology, 24(3), 139-144.
  34. Genazzani, A. D., Prati, A., Santagni, S., Ricchieri, F., Chierchia, E., Rattighieri, E., . . . Artini, P. G. (2012). Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. Gynecological Endocrinology, 28(12), 969-973.
  35. Gerli, S., Mignosa, M., & Di Renzo, G. C. (2003). Effects of inositol on ovarian function and metabolic factors in women with PCOS: A randomized double blind placebo-controlled trial. European Review for Medical and Pharmacological Sciences, 7, 151-159.
  36. Gerli, S., Papaleo, E., Ferrari, A., & Di Renzo, G. C. (2007). Randomized, double blind placebo-controlled trial: Effects of Myo-inositol on ovarian function and metabolic factors in women with PCOS. European Review for Medical and Pharmacological Sciences,11, 347-354.
  37. Giordano, D., Corrado, F., Santamaria, A., Quattrone, S., Pintaudi, B., Benedetto, A. D., & Danna, R. (2011). Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome. Menopause, 18(1), 102-104.
  38. Grazia, S. D., Carlomagno, G., Unfer, V., & Cavalli, P. (2012). Myo-inositol soft gel capsules may prevent the risk of coffee-induced neural tube defects. Expert Opinion on Drug Delivery, 9(9), 1033-1039.
  39. Gulino, F. A., Leonardi, E., Marilli, I., Musmeci, G., Vitale, S. G., Leanza, V., & Palumbo, M. A. (2015). Effect of treatment with myo-inositol on semen parameters of patients undergoing an IVF cycle: In vivo study. Gynecological Endocrinology, 32(1), 65-68.
  40. Guo, X., Guo, S., Miao, Z., Li, Z., & Zhang, H. (2018). Myo-inositol lowers the risk of developing gestational diabetic mellitus in pregnancies: A systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. Journal of Diabetes and Its Complications, 32(3), 342-348.
  41. Hallman, M., Arjomaa, P., & Hoppu, K. (1987). Inositol supplementation in respiratory distress syndrome: Relationship between serum concentration, renal excretion, and lung effluent phospholipids. The Journal of Pediatrics, 110(4), 604-610.
  42. Hallman, M., Jarvenpaa, A. L., & Pohjavuori, M. (1986). Respiratory distress syndrome and inositol supplementation in preterm infants. Archives of Disease in Childhood, 61(11), 1076-1083.
  43. Hallman, M., Bry, K., Hoppu, K., Lappi, M., & Pohjavuori, M. (1992). Inositol supplementation in premature infants with respiratory distress syndrome. The New England Journal of Medicine, 326, 1233-1239.
  44. Harvey, B. H., Scheepers, A., Brand, L., & Stein, D. J. (2001). Chronic inositol increases striatal D2 receptors but does not modify dexamphetamine-induced motor behavior. Pharmacology Biochemistry and Behavior, 68(2), 245-253.
  45. Howlett, A., Ohlsson, A., & Plakkal, N. (2015). Inositol in preterm infants at risk for or having respiratory distress syndrome. Cochrane Database of Systematic Reviews,(2).
  46. Huang, L. C., Fonteles, M. C., Houston, D. B., Zhang, C., & Larner, J. (1993). Chiroinositol deficiency and insulin resistance. III. Acute glycogenic and hypoglycemic effects of two inositol phosphoglycan insulin mediators in normal and streptozotocin-diabetic rats in vivo. Endocrinology, 132(2), 652-657.
  47. Indyk, H., & Committee on Food Nutrition. (2006). Nonvitamin micronutrients. Journal of AOAC International, 89(1), 288-289.
  48. Isabella, R., & Raffone, E. (2012). Concern: Does ovary need d-chiro-inositol? Journal of Ovarian Research, 5(1).
  49. Iuorno, M. J., Jakubowicz, D. J., Baillargeon, J., Dillon, P., Gunn, R. D., Allan, G., & Nestler, J. E. (2002). Effects Of d-chiro-inositol in lean women with the polycystic ovary syndrome. Endocrine Practice, 8(6), 417-423.
  50. Jamilian, M., Farhat, P., Foroozanfard, F., Ebrahimi, F. A., Aghadavod, E., Bahmani, F., . . . Asemi, Z. (2017). Comparison of myo-inositol and metformin on clinical, metabolic and genetic parameters in polycystic ovary syndrome: A randomized controlled clinical trial. Clinical Endocrinology, 87(2), 194-200.
  51. Januszewski, M., Issat, T., Jakimiuk, A. A., Santor-Zaczynska, M., & Jakimiuk, A. J. (2019). Metabolic and hormonal effects of a combined myo-inositol and d-chiro-inositol therapy on patients with polycystic ovary syndrome (PCOS). Ginekologia Polska, 90(1), 7-10.
  52. Kamenov, Z., Kolarov, G., Gateva, A., Carlomagno, G., & Genazzani, A. D. (2014). Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance. Gynecological Endocrinology, 31(2), 131-135.
  53. Katz, D. J., Teloken, P., & Shoshany, O. (2017). Male infertility – The other side of the equation. Australian Family Physician, 46(9), 641-646.
  54. Kennington, A.S., Hill, C.R., Craig, J., Bogardus, C., Raz, I. Ortmeyer, H., … Larner, J. (1990). Low urinary chiro-inositol excretion in non-insulin-dependent diabetes mellitus. New England Journal of Medicine, 323(6), 373-8.
  55. Laganà, A. S., Vitagliano, A., Noventa, M., Ambrosini, G., & D’Anna, R. (2018). Myo-inositol supplementation reduces the amount of gonadotropins and length of ovarian stimulation in women undergoing IVF: A systematic review and meta-analysis of randomized controlled trials. Archives of Gynecology and Obstetrics, 298(4), 675-684.
  56. Lahjouji, K., Aouameur, R., Bissonnette, P., Coady, M.J., Bichet, D.G., & Lapointe, J.Y. (2007). Expression and functionality of the Na+/myo-inositol cotransporter SMIT2 in rabbit kidney. Biochimica et Biophysica Acta, 1768(5), 1154-9.
  57. Lisi, F., Carfagna, P., Oliva, M., Rago, R., Lisi, R., Poverini, R., . . . Moscarini, M. (2012). Pretreatment with myo-inositol in non polycystic ovary syndrome patients undergoing multiple follicular stimulation for IVF: A pilot study. Reproductive Biology and Endocrinology, 10(1), 52.
  58. Macer, M. L., & Taylor, H. S. (2012). Endometriosis and Infertility: A review of the pathogenesis and treatment of endometriosis-associated infertility. Obstetrics and Gynecology Clinics of North America, 39(4), 535-549.
  59. Maeba, R., Hara, H., Ishikawa, H., Hayashi, S., Yoshimura, N., Kusano, J., . . . Teramoto, T. (2008). Myo-inositol treatment increases serum plasmalogens and decreases small dense LDL, particularly in hyperlipidemic subjects with metabolic syndrome. Journal of Nutritional Science and Vitaminology, 54(3), 196-202.
  60. Mancini, M. Andreassi, A., Salvioni, M, Pelliccione, F., Mantellassi, G., & Banderali, G. (2016). Myoinositol and D-chiro inositol in improving insulin resistance in obese male children: Preliminary data. International Journal of Endocrinology, 2016, 8720342.
  61. Matarrelli, B., Vitacolonna, E., D’Angelo, M., Pavone, G., Mattei, P. A., Liberati, M., & Celentano, C. (2013). Effect of dietary myo-inositol supplementation in pregnancy on the incidence of maternal gestational diabetes mellitus and fetal outcomes: A randomized controlled trial. The Journal of Maternal-Fetal & Neonatal Medicine, 26(10), 967-972.
  62. Milewska, E. M., Czyzyk, A., Meczekalski, B., & Genazzani, A. D. (2016). Inositol and human reproduction. From cellular metabolism to clinical use. Gynecological Endocrinology, 32(9), 690-695.
  63. Miñambres, I., Cuixart, G., Gonçalves, A., & Corcoy, R. (2019). Effects of inositol on glucose homeostasis: Systematic review and meta-analysis of randomized controlled trials. Clinical Nutrition, 38(3), 1146-1152.
  64. Minozzi, M., Costantino, D., Guaraldi, C., & Unfer, V. (2011). The effect of a combination therapy with myo-inositol and a combined oral contraceptive pillversusa combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome. Gynecological Endocrinology, 27(11), 920-924.
  65. Monastra, G., Sambuy, Y., Ferruzza, S., Ferrari, D., & Ranaldi, G. (2018). Alpha-lactalbumin effect on myo-inositol intestinal absorption: In vivo and in vitro. Current Drug Delivery, 15(9), 1305-1311.
  66. Montanino Oliva, M., Buonomo, G., Calcagno, M., & Unfer, V. (2018). Effects of myo-inositol plus alpha-lactalbumin in myo-inositol-resistant PCOS women. Journal of Ovarian Research, 11, 38.
  67. Moore, C. M., Breeze, J. L., Kukes, T. J., Rose, S. L., Dager, S. R., Cohen, B. M., & Renshaw, P. F. (1999). Effects of myo-Inositol ingestion on human brain myo-inositol levels: A proton magnetic resonance spectroscopic imaging study. Biological Psychiatry, 45(9), 1197-1202.
  68. Mou, L., & Xie, N. (2017). Male infertility-related molecules involved in sperm-oocyte fusion. Journal of Reproduction and Development, 63(1), 1-7.
  69. Nestler, J. E., Jakubowicz, D. J., Reamer, P., Gunn, R. D., & Allan, G. (1999). Ovulatory and metabolic effects of d-chiro-inositol in the polycystic ovary syndrome. The New England Journal of Medicine, 340(17), 1314-1320.
  70. Pacchiarotti, A., Carlomagno, G., Antonini, G., Pacchiarotti, A. (2016). Effect of myo-inositol and melatonin versus myo-inositol, in a randomized controlled trial, for improving in vitro fertilization of patients with polycystic ovarian syndrome. Gynecological Endocrinology, 32(1), 69-73.
  71. Palatnik, A., Frolov, K., Fux, M., & Benjamin, J. (2001). Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder. Journal of Clinical Psychopharmacology, 21(3), 335-339.
  72. Papaleo, E., Unfer, V., Baillargeon, J., Fusi, F., Occhi, F., & Santis, L. D. (2009). Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertility and Sterility, 91(5), 1750-1754.
  73. Pickerd, N., & Kotecha, S. (2009). Pathophysiology of respiratory distress syndrome. Paediatrics and Child Health, 19(4), 153-157.
  74. Phelps, D. L., Ward, R. M., Williams, R. L., Nolen, T. L., Watterberg, K. L., Oh, W., … Higgins, R. D. (2016). Safety and pharmacokinetics of multiple dose myo-inositol in preterm infants. Pediatric Research,80(2), 209-217.
  75. Pizzo, A., Laganà, A. S., & Barbaro, L. (2013). Comparison between effects of myo-inositol and d-chiro-inositol on ovarian function and metabolic factors in women with PCOS. Gynecological Endocrinology, 30(3), 205-208.
  76. Pkhaladze, L., Barbakadze, L., & Kvashilava, N. (2016). Myo-inositol in the treatment of teenagers affected by PCOS. International Journal of Endocrinology, 2016, 1473612.
  77. Plows, J. F., Stanley, J. L., Baker, P. N., Reynolds, C. M., & Vickers, M. H. (2018). The pathophysiology of gestational diabetes mellitus. International Journal of Molecular Sciences, 19(11), 3342.
  78. Pundir, J., Psaroudakis, D., Savnur, P., Bhide, P., Sabatini, L., Teede, H., . . . Thangaratinam, S. (2017). Inositol treatment of anovulation in women with polycystic ovary syndrome: A meta-analysis of randomised trials. BJOG: An International Journal of Obstetrics & Gynaecology, 125(3), 299-308.
  79. Raffone, E., Rizzo, P., & Benedetto, V. (2009). Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women. Gynecological Endocrinology, 26(4), 275-280.
  80. Rizzo, P., Raffone, E., & Benedetto, V. (2010). Effect of the treatment with myo-inositol plus folic acid plus melatonin in comparison with a treatment with myo-inositol plus folic acid on oocyte quality and pregnancy outcome in IVF cycles. A prospective, clinical trial. European Review for Medical and Pharmacological Sciences, 14(6), 555-61.
  81. Rolland, A.L., Peigné, M., Plouvier, P., Dumont, A., Catteau-Jonard, S., & Dewailly, D. (2017). Could myo-inositol soft gel capsules outperform clomiphene in inducing ovulation? Results of a pilot study. European Review for Medical and Pharmacological Sciences, 21(2 Suppl), 10-14.
  82. Rosenfield, R. L., & Ehrmann, D. A. (2016). The pathogenesis of polycystic ovary syndrome (PCOS): The hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocrine Reviews,37(5), 467-520.
  83. Santamaria, A., Giordano, D., Corrado, F., Pintaudi, B., Interdonato, M. L., Vieste, G. D., . . . Danna, R. (2011). One-year effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome. Climacteric, 15(5), 490-495.
  84. Singh, N., Sharpley, A.L., Emir, U.E., Masaki, C., Herzallah, M.M., Gluck, M.A., … Churchill, G.C. (2016). Effect of the putative lithium mimetic ebselen on brain myo-inositol, sleep, and emotional processing in humans. Neuropsychopharmacology, 41(7), 1768–1778.
  85. Spector, R. (1988). Myo-inositol transport through the blood-brain barrier. Neurochemical Research, 13(8), 785-7.
  86. Spector, R., & Lorenzo, A.V. (1975). Myo-inositol transport in the central nervous system. American Journal of Physiology, 228(5), 1510-18.
  87. Tabrizi, R., Ostadmohammadi, V., Lankarani, K. B., Peymani, P., Akbari, M., Kolahdooz, F., & Asemi, Z. (2018). The effects of inositol supplementation on lipid profiles among patients with metabolic diseases: A systematic review and meta-analysis of randomized controlled trials. Lipids in Health and Disease, 17(1), 123.
  88. Tagliaferri, V., Romualdi, D., Immediata, V., Cicco, S. D., Florio, C. D., Lanzone, A., & Guido, M. (2017). Metformin vs myoinositol: Which is better in obese polycystic ovary syndrome patients? A randomized controlled crossover study. Clinical Endocrinology, 86(5), 725-730.
  89. Thomas, M. P., Mills, S. J., & Potter, B. V. (2016). The “other” inositols and their phosphates: Synthesis, biology, and medicine (with recent advances in myo-Inositol chemistry). Angew Chem Int Ed England, 55(5), 1614-1650.
  90. Unfer, V., Carlomagno, G., Rizzo, P., Raffone, E., & Roseff, S. (2011). Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. European Review for Medical and Pharmacological Sciences, 15(4), 452-457.
  91. Unfer, V., Facchinetti, F., Orrù, B., Giordani, B., & Nestler, J. (2017). Myo-inositol effects in women with PCOS: A meta-analysis of randomized controlled trials. Endocrine Connections, 6(8), 647-658.
  92. Vitagliano, A., Saccone, G., Cosmi, E., Visentin, S., Dessole, F., Ambrosini, G., & Berghella, V. (2018). Inositol for the prevention of gestational diabetes: A systematic review and meta-analysis of randomized controlled trials. Archives of Gynecology and Obstetrics, 299(1), 55-68.
  93. Wozniak, J., Faraone, S.V., Chan, J., Tarko, L., Hernandez, M., Davis, J., … Biederman, J. (2015). A randomized clinical trial of high eicosapentaenoic acid omega-3 fatty acids and inositol as monotherapy and in combination in the treatment of pediatric bipolar spectrum disorders: a pilot study. The Journal of Clinical Psychiatry, 76(11):1548-55.
  94. Zacchè, M. M., Caputo, L., Filippis, S., Zacchè, G., Dindelli, M., & Ferrari, A. (2009). Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecological Endocrinology, 25(8), 508-513.
  95. Zeng, L., & Yang, K. (2017). Effectiveness of myoinositol for polycystic ovary syndrome: A systematic review and meta-analysis. Endocrine, 59(1), 30-38.
  96. Zhang, H., Lv, Y., Li, Z., Sun, L., & Guo, W. (2018). The efficacy of myo-inositol supplementation to prevent gestational diabetes onset: A meta-analysis of randomized controlled trials. The Journal of Maternal-Fetal & Neonatal Medicine, 32(13), 2249-2255.
  97. Zheng, X., Liu, Z., Zhang, Y., Lin, Y., Song, J., Zheng, L., & Lin, S. (2015). Relationship between myo-inositol supplementary and gestational diabetes mellitus. Medicine,94(42).
  98. Zheng, X., Lin, D., Zhang, Y., Lin, Y., Song, J., Li, S., & Sun, Y. (2017). Inositol supplement improves clinical pregnancy rate in infertile women undergoing ovulation induction for ICSI or IVF-ET. Medicine, 96(49).